{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":6,"sponsored":0,"items":[{"id":"n_ixn3wmb7kqo4p3ezcw3a","seq":1367148,"kind":"article","title":"Dukosi opens sampling of DK-NFLNK, a contactless link between battery AFEs and the BMS","url":"https://chargedevs.com/newswire/dukosi-opens-sampling-of-dk-nflnk-a-contactless-link-between-battery-afes-and-the-bms","summary":"Dukosi has made its DK-NFLNK contactless communication solution available for customer sampling. Samples are available to key customers, and Dukosi has also released an evaluation kit. DK-NFLNK is designed for batteries built on conventional multi-channel analog front end (AFE) designs, and Dukosi says it eliminates traditional wiring and connectors by using a single bus antenna.... Read more »","published":"2026-10-02T14:39:50Z","seen":"2026-10-02T14:47:13Z","lang":"en","source":{"id":"kite-chargedevs-com-ad0a24","name":"chargedevs.com","domain":"chargedevs.com"},"via":"kite-chargedevs-com-ad0a24","topics":["auto","newswire","the tech","battery cell design, manufacturing &…","battery pack design & manufacturing","battery technology","circuit protection, contactors & fuses","manufacturing"],"authors":["Chris Ruoff"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"other"}],"story":"st_ixn3wmb7kqo4p3ezcw3a","category":"science-technology","category_p":0.57,"sentiment":"neutral","tone":0.27,"political":0.15},{"id":"n_owxzglig5oupkjjlxhpa","seq":1208834,"kind":"article","title":"Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale","url":"https://www.aol.com/articles/bristol-myers-squibb-vs-johnson-191502000.html","published":"2026-10-01T19:15:00Z","seen":"2026-10-01T20:13:40Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["AOL"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_n5dm5zufwf7hnuspl2ya","category":"economy-business","category_p":0.54,"sentiment":"neutral","tone":0.09,"political":0.03},{"id":"n_2f2k55tqgod7ydyzmlza","seq":862478,"kind":"press_release","title":"CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J","url":"https://www.globenewswire.com/news-release/2026/09/30/3371624/28124/en/car-t-cell-therapy-market-forecasts-growth-from-7-24b-2026-to-13-78b-by-2031-profiling-bristol-myers-squibb-gilead-sciences-novartis-j-j.html","summary":"The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.…","published":"2026-09-30T08:47:00Z","seen":"2026-09-30T08:56:58Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q663596","name":"Gilead Sciences","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_2f2k55tqgod7ydyzmlza","category":"health","category_p":0.48,"category2":"economy-business","sentiment":"neutral","tone":0.15,"political":0.02},{"id":"n_4hilmdkcn5fgoy3xeg4a","seq":560750,"kind":"article","title":"Could Bristol-Myers Squibb (BMY)'s New Myeloma Data Reshape its Growth Outlook?","url":"https://www.insidermonkey.com/news/could-bristol-myers-squibb-bmys-new-myeloma-data-reshape-its-growth-outlook-1846025","published":"2026-09-29T02:15:00Z","seen":"2026-09-29T02:20:13Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","business","science","disaster"],"authors":["Laiba Immad"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"},{"id":"Q8078626","name":"Île Art – Waala Airport","type":"org"},{"id":"Q467635","name":"multiple myeloma","type":"other"}],"story":"st_4hilmdkcn5fgoy3xeg4a","category":"economy-business","category_p":0.36,"category2":"health","sentiment":"neutral","tone":-0.15,"political":0.03},{"id":"n_nhcgxe3g6cekjc4we5pa","seq":535878,"kind":"article","title":"Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue?","url":"https://www.insidermonkey.com/news/bristol-myers-squibb-bmy-is-building-its-next-growth-engine-can-it-replace-lost-revenue-1845255","published":"2026-09-28T22:39:17Z","seen":"2026-09-28T22:39:17Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","disaster","business"],"authors":["Laiba Immad"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"}],"story":"st_nhcgxe3g6cekjc4we5pa","category":"economy-business","category_p":0.92,"sentiment":"positive","tone":-0.12,"political":0.02},{"id":"n_5pmbq6nsu5to3k3jb7ha","seq":316193,"kind":"article","title":"암세포 흔적 더 지웠지만, 감염 늘었다…BMS 골수종 신약의 두 얼굴","title_en":"Cancer cell traces were removed, but infections increased... two faces of BMS's new multiple myeloma drug","url":"https://www.medipana.com/news/articleView.html?idxno=418296","summary":"브리스톨마이어스스퀴브(BMS)의 다발성골수종 신약 \\'젠벡서스(Zenbexus·성분명 이베르도미드)\\'를 포함한 병용요법이 기존 치료 조합보다 더 많은 환자에서 암세포의 흔적을 검출할 수 없는 수준의 깊은 반응을 이끌어냈다. 다만 중증 호중구감소증과 감염은 비교군보다 많이 발생해 치료효과와 안전성을 함께 살펴봐야 한다. BMS가 지난 25일 발표한 임상 3상 \\'EXCALIBER-RRMM\\'의 사전 지정 분석에 따르면, 젠벡서스·다라투무맙·덱사메타손 병용군의 미세잔존질환(MRD) 음성 완전반응률은 41.1%였다. 다라투무맙·보르테조밉·덱사","published":"2026-09-27T22:47:18Z","seen":"2026-09-28T00:23:00Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q266423","name":"Bristol-Myers Squibb","type":"org"}],"story":"st_5pmbq6nsu5to3k3jb7ha","category":"health","category_p":0.82,"sentiment":"negative","tone":-0.51,"political":0.06}]}